



NEWS RELEASE

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

2026-08-03

MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- **Longeveron Inc.** (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

Conference Call and Webcast Details:

Conference Call Number: 1.877.407.0789
Conference ID: 13761959

Call me™ Feature: [Click Here](#)
Webcast: [Click Here](#)

An archived replay of the webcast will be available on the “**Events & Presentations**” section of the Company’s website following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical

needs. The Company's lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on [LinkedIn](#), [X](#), and [Instagram](#).

Investor and Media Contact:

Derek Cole

Investor Relations Advisory Solutions

derek.cole@iradvisory.com

Source: Longeveron